Suche Medizinische Publikationen
Suche Abbildungen und Grafiken
Medizinprodukte - Labortechnik
Antidotarium (Stand 2012)
Phytokodex (Stand 2012)
Endoskopie in Österreich (Stand 2010)
Kardiologie in Österreich (Stand 2006)
Osteologie in Österreich (Stand 2016)
Fachbücher
Patientenliteratur
Waters J, Ashford J, Jäger B, Verboom CN, Wonnacott S Use of moxonidine as initial therapy and in combination in the treatment of essential hypertension - results of the TOPIC (Trial Of Physiotens In Combination) Study Journal of Clinical and Basic Cardiology 1999; 2 (2): 219-224 PDF Summary Overview
| ||
Figure/Graphic 1: TOPIC-Studie - Design Study plan for TOPIC. A = placebo run-in phase (4 weeks; n = 792). B = open-label monotherapy phase (8 weeks; n = 678; moxonidine 200 mcg/day for 4 weeks, then 200 or 400 mcg/day as required). C = moxonidine monotherapy (4 weeks; n = 303; moxonidine 200 or 400 mcg/day as required for 4 weeks). D, E, F = combination therapy (4 weeks; moxonidine [400 mcg/day] plus other agent as specified below). D = moxonidine plus amlodipine (5 mg/day) (n = 87). E = moxonidine plus enalapril (10 mg/day) (n = 88). F = moxonidine plus hydrochlorothiazide (12.5 mg/day) (n = 97). |
Figure/Graphic 1: TOPIC-Studie - Design
Study plan for TOPIC. A = placebo run-in phase (4 weeks; n = 792). B = open-label monotherapy phase (8 weeks; n = 678; moxonidine 200 mcg/day for 4 weeks, then 200 or 400 mcg/day as required). C = moxonidine monotherapy (4 weeks; n = 303; moxonidine 200 or 400 mcg/day as required for 4 weeks). D, E, F = combination therapy (4 weeks; moxonidine [400 mcg/day] plus other agent as specified below). D = moxonidine plus amlodipine (5 mg/day) (n = 87). E = moxonidine plus enalapril (10 mg/day) (n = 88). F = moxonidine plus hydrochlorothiazide (12.5 mg/day) (n = 97). |